Gordian Biotechnology, an in vivo drug discovery and development company, has unveiled an innovative platform that enables patient-predictive in vivo screening of gene targets for FDA-recognized diseases of aging at an unprecedented scale. This groundbreaking platform has the potential to revolutionize the development of therapies for a wide range of age-related ailments.